The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Open accessAbstract
NLR inflammasomes, caspase 1 activation platforms critical for processing key pro-inflammatory cytokines, have been implicated in the development of nonalcoholic fatty liver disease (NAFLD). As the direct role of the NLRP3 inflammasome remains unclear, we tested effects of persistent NLRP3 activation as a contributor to NAFLD development and, in particular, as a modulator of progression from benign hepatic steatosis to steatohepatitis during diet-induced NAFLD. Gain of function tamoxifen-inducible Nlrp3 knock-in mice allowing for in vivo temporal control of NLRP3 activation and loss of function Nlrp3 knockout mice were placed on short-term choline-deficient amino acid-defined (CDAA) diet, to induce isolated hepatic steatosis or long-term CDAA exposure, to induce severe steatohepatitis and fibrosis, respectively. Expression of NLRP3 associated proteins was assessed in liver biopsies of a well-characterized group of patients with the full spectrum of NAFLD. Nlrp3(-/-) mice were protected from long-term feeding CDAA-induced hepatomegaly, liver injury, and infiltration of activated macrophages. More importantly, Nlrp3(-/-) mice showed marked protection from CDAA-induced liver fibrosis. After 4 weeks on CDAA diet, wild-type (WT) animals showed isolated hepatic steatosis while Nlrp3 knock-in mice showed severe liver inflammation, with increased infiltration of activated macrophages and early signs of liver fibrosis. In the liver samples of patients with NAFLD, inflammasome components were significantly increased in those patients with nonalcoholic steatohepatitis (NASH) when compared to those with non-NASH NAFLD with mRNA levels of pro-IL1 beta correlated to levels of COL1A1. Our study uncovers a crucial role for the NLRP3 inflammasome in the development of NAFLD. These findings may lead to novel therapeutic strategies aimed at halting the progression of hepatic steatosis to the more severe forms of this disease. Key message: Mice with NLRP3 inflammasome loss of function are protected from diet-induced steatohepatitis. NLRP3 inflammasome gain of function leads to early and severe onset of diet-induced steatohepatitis in mice. Patients with severe NAFLD exhibit increased levels of NLRP3 inflammasome components and levels of pro-IL1β mRNA correlate with the expression of COL1A1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sen cells showed altered lipid-transport and lipoprotein-remodelling traits (Fig. 3a), consistent with the ability of oxidative stress to generate lipotoxicity that triggers inflammation and fibrosis30.”
From Senescence atlas reveals an aged-like inflamed niche that blunts muscle regeneration (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Self-citationThe NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Self-citationFatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698
Cited by
Sorted by citations
Items 101–200 of 485
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Jennison, E., & Byrne, C. D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0129 · Cited by 91
Gut microbiota and systemic immunity in health and disease
Lo, B. C., Chen, G., Núñez, G., & Caruso, R. (2020) · International Immunology · doi:10.1093/intimm/dxaa079 · Cited by 90
Zhou, J., Tripathi, M., Ho, J. P., Widjaja, A. A., Shekeran, S. G., Camat, M. D., James, A., Wu, Y., Ching, J., Kovalik, J., et al. (2022) · Thyroid · doi:10.1089/thy.2021.0621 · Cited by 86
Çınar, R., Iyer, M. R., Liu, Z., Cao, Z., Jourdan, T., Erdélyi, K., Godlewski, G., Szanda, G., Liu, J., Park, J. K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87336 · Cited by 86
Galectin‐3 regulates inflammasome activation in cholestatic liver injury
Tian, J., Yang, G., Chen, H., Hsu, D. K., Tomilov, A. A., Olson, K., Dehnad, A., Fish, S. R., Cortopassi, G. A., Zhao, K., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600392rr · Cited by 84
RIP Kinases in Liver Cell Death, Inflammation and Cancer
Kondylis, V., & Pasparakis, M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.007 · Cited by 85
Zhang, W., Fang, Z., & Liu, W. (2019) · Parasites & Vectors · doi:10.1186/s13071-018-3223-8 · Cited by 86
Innate immune regulatory networks in hepatic lipid metabolism
Bai, L., & Li, H. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01765-1 · Cited by 86
Self-citationPierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
From Innate Immunity to Metabolic Disorder: A Review of the NLRP3 Inflammasome in Diabetes Mellitus
Nițulescu, I. M., Ciulei, G., Cozma, A., Procopciuc, L. M., & Orasan, O. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186022 · Cited by 83
MicroRNAs as important regulators of the NLRP3 inflammasome
Zamani, P., Oskuee, R. K., Atkin, S. L., Navashenaq, J. G., & Sahebkar, A. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.05.004 · Cited by 80
Lipid regulation of NLRP3 inflammasome activity through organelle stress
Liang, J. J., Fraser, I. D. C., & Bryant, C. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.07.005 · Cited by 79
Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Mastrocola, R., Aragno, M., Alloatti, G., Collino, M., Penna, C., & Pagliaro, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407123522 · Cited by 76
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77
ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model
Gaul, S., Geisler, L. J., McGeough, M. D., Johnson, C. D., Zagórska, A., Li, L., Wree, A., Barry, V., Mikaelian, I., Jih, L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.123294 · Cited by 77
Self-citationShi, W., Xu, G., Zhan, X., Gao, Y., Wang, Z., Fu, S., Qin, N., Hou, X., Ai, Y., Wang, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2460-x · Cited by 76
Zhou, L., Qiu, X., Meng, Z., Liu, T., Chen, Z., Zhang, P., Kuang, H., Pan, T., Lu, Y., Qi, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1866 · Cited by 85
The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis
Tao, Y., Wang, N., Qiu, T., & Sun, X. (2020) · BioMed Research International · doi:10.1155/2020/7269150 · Cited by 74
Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
Oates, J. R., McKell, M. C., Moreno‐Fernandez, M. E., Damen, M. S. M. A., Deepe, G. S., Qualls, J. E., & Divanovic, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02893 · Cited by 78
Pezzino, S., Sofia, M., Faletra, G., Mazzone, C., Litrico, G., Greca, G. L., & Latteri, S. (2022) · Biology · doi:10.3390/biology11111622 · Cited by 77
Zou, Y., Chen, Z., Sun, C., Yang, D. K., Zhou, Z., Peng, X., Zheng, L., & Tang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010940 · Cited by 76
Chen, T.-X., Meng, Y., Zhou, Z.-H., Li, H., Wan, L.-F., Kang, A., Guo, W., Ren, K., Song, X., Chen, Y., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01183-4 · Cited by 66
Self-citationCellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Development
Ignat, S.-R., Dinescu, S., Hermenean, A. O., & Costache, M. (2020) · Cells · doi:10.3390/cells9020461 · Cited by 75
Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 77
NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression
Latif, M. U., Schmídt, G., Mercan, S., Rahman, R., Gibhardt, C. S., Stejerean‐Todoran, I., Reutlinger, K., Heßmann, E., Singh, S. K., Moeed, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325013 · Cited by 71
Pavillard, L. E., Cañadas-Lozano, D., Alcocer‐Gómez, E., Marín‐Aguilar, F., Pereira, S., Robertson, A. A. B., Muntané, J., Ryffel, B., Cooper, M. A., Quiles, J. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20763 · Cited by 72
Qin, Y., Gu, T., Ling, J., Luo, J., Zhao, J., Hu, B., Hua, L., Wan, C., & Jiang, S. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4258 · Cited by 71
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 71
Targeting cell death in NAFLD: mechanisms and targeted therapies
Xu, H., Wan, S., An, Y., Wu, Q., Xing, Y.-H., Deng, C.-H., Zhang, P., Long, Y., Xu, B.-T., & Jiang, Z. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02168-z · Cited by 72
The relevance of pyroptosis in the pathogenesis of liver diseases
Guo, H., Xie, M., Zhou, C., & Zheng, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.060 · Cited by 67
Mirea, A.-M., Stienstra, R., Kanneganti, T., Tack, C. J., Chavakis, T., Toonen, E. J. M., & Joosten, L. A. B. (2020) · Inflammation · doi:10.1007/s10753-020-01190-4 · Cited by 67
Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome
Yang, G., Jang, J. H., Kim, S. W., Han, S., Ma, K., Jang, J.-K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082790 · Cited by 67
Ge, C., Xu, M., Qin, Y., Gu, T.-T., Feng, J., Jinxiao, L., Sujun, W., Ma, Y., Deshuai, L., Qiang, L., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.12.034 · Cited by 63
Hernández, A., Geng, Y., Sepúlveda, R., Solı́s, N., Torres, J., Arab, J. P., Francisco Barrera, M., Cabrera, D., Moshage, H. J., & Arrese, M. A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165753 · Cited by 64
NLRP3 inflammasome in health and disease (Review)
Wang, H., Ma, L., Su, W., Liu, Y., Xie, N., & Liu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5489 · Cited by 70
Lee, H. J., Hong, Y., Jun, W., & Yang, S. J. (2015) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3439 · Cited by 63
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Ramos‐Tovar, E., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115861 · Cited by 66
Morrison, M. C., Mulder, P., Salic, K., Verheij, J., Liang, W., van Duyvenvoorde, W., Menke, A. L., Kooistra, T., Kleemann, R., & Wielinga, P. Y. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.74 · Cited by 63
NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation
Neumann, K., Schiller, B., & Tiegs, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092732 · Cited by 64
Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease
Aragonès, G., González-García, S., Aguilar, C., Richart, C., & Auguet, T. (2019) · BioMed Research International · doi:10.1155/2019/8507583 · Cited by 69
Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?
Wallert, M., Börmel, L., & Lorkowski, S. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000097 · Cited by 68
Calcagno, D. M., Chu, A., Gaul, S., Taghdiri, N., Toomu, A., Leszczynska, A., Kaufmann, B. K., Papouchado, B. G., Wree, A., Geisler, L. J., et al. (2022) · Hepatology · doi:10.1002/hep.32320 · Cited by 62
Self-citationHigd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice
Zhu, J., Chen, M., Mu, W.-J., Luo, H.-Y., & Guo, L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155241 · Cited by 62
Effect of Gut Microbiota on Blood Cholesterol: A Review on Mechanisms
Deng, C., Pan, J., Zhu, H., & Chen, Z. (2023) · Foods · doi:10.3390/foods12234308 · Cited by 70
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
αB-Crystallin Regulates Subretinal Fibrosis by Modulation of Epithelial-Mesenchymal Transition
Ishikawa, K., Sreekumar, P. G., Spee, C. K., Nazari, H. K., Zhu, D., Kannan, R., & Hinton, D. R. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.014 · Cited by 61
Soleimani, D., Rezaie, M., Rajabzadeh, F., Navashenaq, J. G., Abbaspour, M., Miryan, M., Razmpour, F., Ranjbar, G., Rezvani, R., Jarahi, L., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6937 · Cited by 64
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities
García‐Pras, E., Fernández‐Iglesias, A., Gracia‐Sancho, J., & Pérez‐del‐Pulgar, S. (2021) · Cancers · doi:10.3390/cancers14010048 · Cited by 62
Yu, W., Sun, S., Yan, Y., Zhou, H., Liu, Z., & Fu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1519925 · Cited by 70
Sayed, R. K. A., Fernández‐Ortiz, M., Díaz-Casado, M. E., Aranda‐Martínez, P., Fernández‐Martínez, J., Guerra‐Librero, A., Escames, G., López, L. C., Alsaadawy, R. M., & Acuña-Castroviejo, D. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz079 · Cited by 59
Yang, W., Liu, L., Wei, Y., Fang, C., Liu, S., Zhou, F., Li, Y., Zhao, G., Guo, Z., Luo, Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00508-y · Cited by 58
Eguchi, A., Yoshitomi, T., Lazić, M., Johnson, C. D., Vong, L. B., Wree, A., Povero, D., Papouchado, B. G., Nagasaki, Y., & Feldstein, A. E. (2015) · Nanomedicine · doi:10.2217/nnm.15.87 · Cited by 59
Self-citationSun, N.-N., Yu, C., Pan, M., Zhang, Y., Zheng, B., Yang, Q., Zheng, Z., & Meng, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13305-3 · Cited by 59
Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
Li, X., & Wang, H. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00507-y · Cited by 59
Charan, H. V., Dwivedi, D. K., Khan, S., & Jena, G. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.006 · Cited by 58
Liu, Y., Kong, X., You, Y., Xiang, L., Zhang, Y., Wu, R., Zhou, L., & Duan, L. (2022) · Cells · doi:10.3390/cells11223579 · Cited by 54
Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., Kock, J. D., Vanhaecke, T., & Rodrigues, R. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.029 · Cited by 55
Pirozzi, C., Lama, A., Annunziata, C., Cavaliere, G., Ruiz‐Fernández, C., Monnolo, A., Comella, F., Gualillo, O., Stornaiuolo, M., Mollica, M. P., et al. (2020) · Antioxidants · doi:10.3390/antiox9121201 · Cited by 51
Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.
Bieghs, V., & Trautwein, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.12.04 · Cited by 54
Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease
Nababan, S. H. H., Nishiumi, S., Kawano, Y., Kobayashi, T., Yoshida, M., & Azuma, T. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.04.009 · Cited by 53
Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis
Wree, A., Mehal, W. Z., & Feldstein, A. E. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571272 · Cited by 52
Self-citationNigro, D., Menotti, F., Cento, A. S., Serpe, L., Chiazza, F., Bello, F. D., Romaniello, F., Medana, C., Collino, M., Aragno, M., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.01.010 · Cited by 52
Hou, L., Zhang, Z., Yang, L., Chang, N., Zhao, X., Zhou, X., Yang, L., & Li, L. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02032-4 · Cited by 51
Kaufmann, B., Kui, L., Reca, A., Leszczynska, A., Kim, A. D., Booshehri, L. M., Wree, A., Friess, H., Hartmann, D., Broderick, L., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.007 · Cited by 51
Self-citationNatural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Pan, J., Zhou, W., Xu, R., Xing, L., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113127 · Cited by 50
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis
Baeza-Raja, B., Goodyear, A., Liu, X., Lam, K., Yamamoto, L., Li, Y., Dodson, G. S., Takeuchi, T., Kisseleva, T., Brenner, D. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234038 · Cited by 53
Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases
Özenver, N., & Efferth, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105710 · Cited by 54
Saha, M., Manna, K., & Saha, K. D. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s343236 · Cited by 48
NLRP3 inflammasome activation mechanism and its role in autoimmune liver disease
Guan, Y., Gu, Y., Li, H., Liang, B., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022137 · Cited by 48
Self-citationFungal infections and the fungal microbiome in hepatobiliary disorders
Hartmann, P., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.006 · Cited by 50
Clinical implications of understanding the association between oxidative stress and pediatric NAFLD
Mann, J. P., Raponi, M., & Nobili, V. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1291340 · Cited by 48
Yong, Z., Ruiqi, W., Hongji, Y., Ning, M., Chenzuo, J., Yu, Z., Zhixuan, X., Qiang, L., Qibing, L., Weiying, L., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/4084566 · Cited by 48
Tian, C., Min, X., Zhao, Y., Wang, Y., Wu, X., Liu, S., Dou, W., Zhou, T., Liu, Y., Luo, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.017 · Cited by 49
Ma, X., Zhou, Y., Qiao, B., Jiang, S., Shen, Q., Han, Y., Liu, A., Chen, X., Wei, L., Zhou, L., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00427.2019 · Cited by 47
Shi, Y.-S., Li, X., Li, H., & Zhang, Y. (2020) · Food & Function · doi:10.1039/d0fo00660b · Cited by 47
Self-citationGao, Y., Xu, G., Ma, L., Shi, W., Wang, Z., Zhan, X., Qin, N., He, T., Guo, Y., Niu, M., et al. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00647-1 · Cited by 47
Pyroptosis in Steatohepatitis and Liver Diseases
Knorr, J., Wree, A., & Feldstein, A. E. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167271 · Cited by 48
Self-citationTao, Y., Qiu, T., Yao, X., Jiang, L., Wang, N., Jia, X., Wei, S., Wang, Z., Pei, P., Zhang, J., et al. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.124959 · Cited by 46
Sehlmeyer, K., Ruwisch, J., Roldán, N., & López-Rodríguez, E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00386 · Cited by 46
Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
Ding, N., Wei, B., Fu, X., Wang, C., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.591393 · Cited by 51
Zhu, X., Lin, X., Zhang, P., Liu, Y., Ling, W., & Guo, H. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101843 · Cited by 46
Kuo, N.-C., Huang, S.-Y., Yang, C., Shen, H., & Lee, Y. (2020) · Antioxidants · doi:10.3390/antiox9100924 · Cited by 44
Mohamed, I., Li, L., Ismael, S., Ishrat, T., & El‐Remessy, A. B. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.1979 · Cited by 47
NLRP3 activation in neutrophils induces lethal autoinflammation, liver inflammation, and fibrosis
Kaufmann, B. K., Leszczynska, A., Reca, A., Booshehri, L. M., Onyuru, J., Tan, Z., Wree, A., Friess, H., Hartmann, D., Papouchado, B. G., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154446 · Cited by 44
Self-citationNonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
Roles of immune dysregulation in MASLD
Dong, T., Li, J., Liu, Y., Zhou, S., Wei, X., Hua, H., Tang, K., Zhang, X., Wang, Y., Wu, Z. F., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116069 · Cited by 43
Yan, B., Wang, Y., Wang, W., Ding, X., Wei, B., Liu, S., Fu, T., Chen, L., Zhang, J.-Z., Liu, J., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115999 · Cited by 40
Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development
Arsenijević, A., Stojanović, B., Milovanović, J., Arsenijević, D., Arsenijević, N., & Milovanović, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145097 · Cited by 40
Bashiri, A., Nesan, D., Tavallaee, G., Sue-Chue-Lam, I., Chien, K., Maguire, G. F., Naples, M., Zhang, J., Magomedova, L., Adeli, K., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.005 · Cited by 41
Lu, Y., Zhong, S., Meng, N., Fan, Y.-P., & Tang, W.-X. (2017) · Scientific Reports · doi:10.1038/s41598-017-08689-1 · Cited by 39
Chen, H., Yen, C., Kuo, L.-L., Lo, C., Huang, C., Chen, C.-C., & Lii, C. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114941 · Cited by 40
Longo, L., Ferrari, J. T., Rampelotto, P. H., Dellavia, G. H., Pasqualotto, A., de Oliveira, C. P. M. S., Cerski, C. T. S., da Silveira, T. R., Cruz, C. U., & Álvares‐da‐Silva, M. R. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s262879 · Cited by 39
Nobiletin mitigates NAFLD via lipophagy and inflammation
Yang, X., Deng, Y., Tu, Y., Feng, D., & Liao, W. (2022) · Food & Function · doi:10.1039/d2fo01682f · Cited by 39
Putnam, C. D., Broderick, L., & Hoffman, H. M. (2023) · Immunological Reviews · doi:10.1111/imr.13292 · Cited by 42
Self-citationMechanisms of nonalcoholic fatty liver disease and implications for surgery
Kaufmann, B. K., Reca, A., Wang, B., Friess, H., Feldstein, A. E., & Hartmann, D. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01965-1 · Cited by 39
Self-citationObesity, COVID-19 and innate immunometabolism
Gleeson, L. E., Roche, H. M., & Sheedy, F. J. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003529 · Cited by 39
Hwangbo, H., Kim, M. Y., Ji, S. Y., Kim, S. Y., Lee, H., Kim, G., Park, C., Keum, Y., Hong, S. H., Cheong, J., et al. (2020) · Antioxidants · doi:10.3390/antiox9111040 · Cited by 38
Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease
Liedtke, C., Nevzorova, Y. A., Luedde, T., Zimmermann, H. W., Kroy, D. C., Strnad, P., Berres, M., Bernhagen, J., Tacke, F., Nattermann, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.814496 · Cited by 43
Self-citation
Metadata
- Authors
- Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E.
- Affiliations
- University of California San Diego (US)
- Essen University Hospital (DE)
- Corresponding author
- Feldstein, Ariel E.
- ORCID
- Venue
- Journal of Molecular Medicine
- Published
- 2014-05-28
- Volume
- 92
- Issue
- 10
- Pages
- 1069-1082
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- PMC
- PMC4349416
- OpenAlex
- W1977508200
- Cited by
- 486
- References
- 43
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 31 · 2023: 64 · 2022: 66 · 2021: 63 · 2020: 69 · 2019: 27 · 2018: 37 · 2017: 33 · 2016: 27 · 2015: 17 · 2014: 3
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA022489)
- National Cancer Institute (P30CA023100)
- National Institute of Allergy and Infectious Diseases (AI52430, R01AI052430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082451, R01DK076852, DK082451, DK-076852)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- NLRP3 inflammasome, non-alcoholic fatty liver disease, liver fibrosis, steatohepatitis, hepatic steatosis, NLRP3 knockout mice, pro-IL-1β, COL1A1, macrophage infiltration, liver inflammation, caspase-1
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Collagen Type I, alpha 1 Chain, Animals, Carrier Proteins, Female, Fibrosis, Humans, Liver, Male, Mice, Transgenic, RNA, Messenger, Collagen Type I, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
